Inebilizumab

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Generalized Myasthenia Gravis

Conditions

Generalized Myasthenia Gravis

Trial Timeline

Apr 30, 2026 → Mar 13, 2030

NCT ID

NCT06987539

About Inebilizumab

Inebilizumab is a phase 2 stage product being developed by Amgen for Generalized Myasthenia Gravis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06987539. Target conditions include Generalized Myasthenia Gravis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06987539	Phase 2	Recruiting	Apr 30, 2026	Mar 13, 2030	Generalized Myasthenia Gravis
NCT07222553	Phase 2	Recruiting	Apr 3, 2026	Jun 10, 2031	Immunoglobulin G4-related Disease
NCT06180278	Approved	Active	Apr 2, 2024	Jun 26, 2028	Neuromyelitis Optica Spectrum Disorder
NCT05549258	Phase 2	Recruiting	Jul 3, 2023	Apr 13, 2027	Neuromyelitis Optica Spectrum Disorder
NCT04540497	Phase 3	Active	Dec 4, 2020	Oct 31, 2028	IgG4 Related Disease

Competing Products

20 competing products in Generalized Myasthenia Gravis

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + placebo	Eli Lilly	Phase 2/3	65
Satralizumab	Chugai Pharmaceutical	Phase 3	77
Perampanel	Eisai	Pre-clinical	23
Perampanel + Placebo comparator	Eisai	Phase 3	77
zonisamide	Eisai	Pre-clinical	23
Fycompa	Eisai	Pre-clinical	23
Fycompa	Eisai	Pre-clinical	23
Perampanel	Eisai	Phase 3	77
Perampanel	Eisai	Pre-clinical	23
Cenobamate	Ono Pharmaceutical	Phase 3	77
Duloxetine + Placebo	Eli Lilly	Phase 3	77
Duloxetine + Placebo	Eli Lilly	Approved	85
Ixekizumab	Eli Lilly	Approved	85
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	52
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	85
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	52
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	52
ABBV-932 + Placebo	AbbVie	Phase 1	33
Escitalopram	AbbVie	Approved	85
Adalimumab	AbbVie	Phase 3	77

Other Products from Amgen